New Malaria Vaccine Candidate Shows Promise in Preclinical Tests

A dual-stage, heat-stable vaccine developed by Griffith University researchers addresses key limitations of current malaria vaccines, including short-lived immunity and strict cold-chain storage requirements.

Vaccine Mechanism and Targets

The candidate vaccine uses engineered bacteria to produce particles that display key malaria proteins. This approach trains the immune system by targeting two distinct stages of the malaria parasite's life cycle:

• Liver stage: Preventing infection before it establishes in the liver.
• Transmission stage: Blocking the parasite's ability to be transmitted from humans to mosquitoes.

Preclinical Performance

In laboratory tests, the vaccine candidate produced significant results:

• Reduced liver infection by up to 80% in test subjects.
• Provided complete protection from developing malaria in 25% of subjects (one in four).
• Generated antibody levels described as well above protective thresholds.
• Diminished parasite transmission by mosquitoes by approximately two-thirds (66%).
• Induced immunity that persisted for at least six months.

Thermal Stability and Distribution

The vaccine remains stable and effective for a minimum of one month when stored at 37°C (98.6°F).

This characteristic eliminates the need for continuous cold-chain storage, a requirement for current malaria vaccines that poses logistical challenges in remote and rural areas.

Statements from Researchers

Professor Bernd Rehm, Director of the Centre for Cell Factories and Biopolymers at Griffith University, stated that existing vaccines provide partial and short-lived protection and require strict refrigeration. He said the new vaccine targets two critical stages: before infection and during transmission.

Dr. Nivethika Sivakumaran, lead author, noted that maintaining cold temperatures for vaccines is a significant challenge in malaria-affected regions.

Dr. Shuxiong Chen, co-author, stated that the vaccine remains stable and effective for at least a month at 37°C, which he said improves access.

Background Context

• Malaria is a mosquito-borne disease that kills over 500,000 people annually.
• Currently available vaccines have limited efficacy and require cold-chain logistics for storage and transport.
• The Griffith University candidate remains at the preclinical stage, with human trials not yet conducted.